Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956024 | 0.85 | GRM5 (0.35) | GRM5GRM1PDK4NAMPT | |
| SCHEMBL8195218 | 0.80 | NAMPT (0.57) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL23210245 | 0.79 | PDK4 (0.60) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL1366854 | 0.77 | PDK4 (0.52) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL31009246 | 0.77 | PDK4 (0.52) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL4006887 | 0.76 | GRM1 (0.56) | GRM5GRM1PDK4GPR119WNT3A | |
| SCHEMBL15146264 | 0.76 | GRM1 (0.56) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL31444026 | 0.76 | PDK4 (0.53) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL31510790 | 0.76 | NAMPT (0.52) | GRM5GRM1PDK4NAMPTHTR6 | |
| SCHEMBL30913564 | 0.76 | GRM1 (0.56) | GRM5GRM1PDK4GPR119WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | GRM5 768/4885GRM1 572/4885PDK4 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.